APA (7th ed.) Citation

I, F., L, B., R, S., V, C., C, E., R, F., . . . E, J. (2024). Combined therapy targeting AR and EZH2 curbs castration-resistant prostate cancer enhancing anti-tumor T-cell response. Epigenomics. https://doi.org/10.2217/epi-2023-0374

Chicago Style (17th ed.) Citation

I, Fischetti, et al. "Combined Therapy Targeting AR and EZH2 Curbs Castration-resistant Prostate Cancer Enhancing Anti-tumor T-cell Response." Epigenomics 2024. https://doi.org/10.2217/epi-2023-0374.

MLA (9th ed.) Citation

I, Fischetti, et al. "Combined Therapy Targeting AR and EZH2 Curbs Castration-resistant Prostate Cancer Enhancing Anti-tumor T-cell Response." Epigenomics, 2024, https://doi.org/10.2217/epi-2023-0374.